Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the appointment of Amanda Morgan as Senior Vice President, Commercial. Ms. Morgan will report to Paul Blanchfield, Lantheus' Chief Operating Officer, and will be responsible for leading all of the Company's commercial activities, including Sales, Marketing, and Market Access.

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

Quarterly revenue grew 134% YoY to $239.3mm, driven by strengths across the portfolio. Management raised Q4 and FY22 guidance to the upside from the top-bottom lines.

Lantheus: Sell Thesis Missing These Key Factors

QuidelOrtho Corp

TG Therapeutics

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

3 Medical Products Stocks Navigating Industry Challenges (Revised)

Celsius Holdings

PDC Energy Inc

Bloomberg Law recently discussed the global mergers and acquisitions (M&A) market. Their analysis pointed out that even though the 2022 M&A volume is down from a record number of transactions in 2021, the potential deals in 2023 could be pretty standard relative to the pre-pandemic volume.

3 Stocks That Could Be the Next Big M&A Targets

Axsome Therapeutics

DiCE Molecules Holding LLC

The good times could keep on rolling for these big winners.

These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Mark Kinarney - VP, IR Mary Heino - President and CEO Paul Blanchfield – COO Robert Marshall - CFO and Treasurer Conference Call Participants Roanna Ruiz - SVB Securities Larry Solow - CJS Securities Anthony Petrone - Mizuho Group Richard Newitter - Tuist Matt Taylor - Jefferies Justin Walsh - Jones Trading Yuan Zhi - B. Riley Operator Good morning, and welcome to the Lantheus Third Quarter 2022 Conference Call.

Lantheus Holdings, Inc. (LNTH) Q3 2022 Earnings Call Transcript

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 19.28% and 4.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Tops Q3 Earnings and Revenue Estimates

NORTH BILLERICA, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today reported financial results for its third quarter ended September 30, 2022.

Lantheus Reports Third Quarter 2022 Financial Results

Lantheus Holdings (LNTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why "Trend" Investors Would Love Betting on Lantheus Holdings (LNTH)

NORTH BILLERICA, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022, to discuss its financial and operating results for the third quarter of 2022.

Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time

Lantheus Holdings (LNTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lantheus Holdings (LNTH) Upgraded to Buy: What Does It Mean for the Stock?

NORTH BILLERICA, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain.

Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data

Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Lantheus Holdings (LNTH) is Poised to Beat Earnings Estimates Again

Payoneer Global

VOC Energy

Top stock Payoneer breaks out from a cup base as it joins a small cap index and gains favorable analyst coverage. The post Top Stock Breaks Out After This Payment Processor Joins Small-Cap Index appeared first on Investor's Business Daily.

Top Stock Breaks Out After This Payment Processor Joins Small-Cap Index

Calumet Inc

Hudson Technologies

iRhythm Technologies

Karuna Therapeutics Inc

Liquidia Technologies Inc

Veru

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.

7 Momentum Stocks to Buy Now for Extraordinary Gains

Lantheus Holdings' Definity continues to grow. But its new Pylarify imaging tool underpins triple-digit gains for LNTH stock.

A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock

ModivCare

Shockwave Medical

The healthcare business offers attractive defensive attributes that are so valuable in the current uncertain environment. As such, adding healthcare stocks to the portfolio brings much needed diversification.

3 Top Ranked Stocks for Exposure to the Medical Sector

Cavco Industries

Perion Network

Pure Storage

Here are four top-ranked liquid stocks, Lantheus (LNTH), Cavco (CVCO), Pure Storage (PSTG) and Perion Network (PERI), which investors can add to their portfolio for returns.

4 Top-Performing Liquid Stocks for Attractive Returns in 2022

CHALFONT ST GILES, United Kingdom and NORTH BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD). The findings, shared at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida, U.S., also demonstrate [18F]flurpiridaz Positron Emission Tomography (PET) has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), the predominant procedure used in nuclear cardiology today. SPECT MPI represents approximately 6 million procedures per year in the U.Si.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Alliance Resource Partners

Carter Bankshares

Digi

MGP Ingredients

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MGPI, LNTH, CARE, ARLP and DGII.

5 Stocks With Recent Price Strength in an Uncertain September

Dave & Buster's

LiveRamp Holdings Inc

For those investors interested in small-cap stocks to buy, you might steer clear of tech names. At least, that's according to the analysts at Jefferies.

3 Small-Cap Stocks That Could 10X by 2027

NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial intelligence solutions that empower clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, and Paul Blanchfield, Chief Operating Officer, will present at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Thursday, September 8.

Lantheus to Present at the Wells Fargo Healthcare Conference

The consensus price target hints at a 26.4% upside potential for Lantheus Holdings (LNTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Lantheus Holdings (LNTH) Have the Potential to Rally 26% as Wall Street Analysts Expect?

Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Lantheus Holdings, Inc. (LNTH) Soars to 52-Week High, Time to Cash Out?

Bio-Rad Laboratories

Haemonetics

Zimmer Biomet Hlds

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

News for Lantheus Holdings Stock (LNTH)